Zacks Investment Research
20 Jul 2026, 22:51 UTC · 6w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Moderna (MRNA) is expected to report an EPS of -$1.97 for the upcoming quarter ending July 31, 2026. — The projection of continued losses typically puts downward pressure on a stock's valuation despite the slight year-over-year improvement.
-0.30The Zacks Consensus Estimate projects Moderna's quarterly net sales to be $126.65 million, a 10.81% decrease from the prior-year period. — A double-digit decline in quarterly revenue indicates shrinking top-line growth, which is a negative signal for investors.
-0.30The Zacks Consensus EPS estimate for Moderna has shifted 1.51% upward over the past month. — Upward revisions in earnings estimates are generally viewed as a positive indicator for near-term stock performance.
+0.20Continue reading
6 related stories
Top 2 movers · tap to explore
Moderna currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating suggests a neutral outlook with no immediate strong catalyst for buying or selling.
+0.00Which stocks this story touches
The stock closed down 3.77% and has lagged the S&P 500 and its sector over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
